FDA Clears Lucid-MS for Phase 2 DevelopmentThe Company announced Monday that the FDA has approved its Investigational New Drug application for Lucid-MS (Lucid-21-302), enabling Quantum BioPharma to advance its multiple sclerosis program into Phase 2 clinical development. Quantum BioPharma intends to begin patient enrollment and dosing as swiftly as possible. "This Phase 2 trial marks an important strategic milestone for Quantum BioPharma and advances our unique Lucid-MS program into the next stage of development," said Zeeshan Saeed, Founder, CEO, and Executive Co-Chairman of the Board of Quantum BioPharma. Quantum BioPharma Ltd. (QNTM) is an unaffiliated third party and did not commission, sponsor, review, or pay for this communication; the compensation described above was paid solely by FinnCom, Inc. The information contained in this article is derived exclusively from public press releases, SEC filings, and other official disclosures issued by Quantum BioPharma Ltd. No independent verification has been performed by the publisher.